FindTrial
Sign In

ephrin B2 as a novel circulating fibrosis biomarker for heart failure

ephrin B2 as a novel circulating fibrosis biomarker for heart failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800017043
Enrollment
Unknown
Registered
2018-07-09
Start date
2018-07-01
Completion date
Unknown
Last updated
2018-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

Gold Standard:Framingham criteria
Index test:Ephrin-B2

Sponsors

The Second Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: case group: clinical diagnosis of heart failure with good compliance; control group: inpatients due to non-heart failure diseases during the period.

Exclusion criteria

Exclusion criteria: 1. age<18 years old; 2. acute coronary syndrome emerged during the past 6 months; 3. renal failure; 4. cirrhosis and liver cancer; 5. Peripheral Vascular Diseases; 6. autoimmune disease,such as SLE RA.

Design outcomes

Primary

MeasureTime frame
ephrin B2;—

Countries

China

Contacts

Public ContactZhang Xiangyu

The Second Xiangya Hospital of Central South University

13707486860@163.com+86 13707486860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026